Butyrate supplementation restores microglial phagocytic capacity in germ-free APP/PS1 mice, associated with upregulation of TREM2 and CD33, two important receptors involved in Aβ clearance and AD risk [63]. This evidence concerns the gene APP and Alzheimer disease.